7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
SYSTEMS GLYCOBIOLOGY OF GASTRIC CANCER (GASTRICGLYCOEXPLORER)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2018,
...O-glycosylation in gastric cancer for training in systems glycobiology. For meeting the needs of the research goal and for training for future systems glycobiology operations, cross disciplinary international institutes have been identified with top level state-of-the-art glycobioanalytical, glycotechnological and glycobioinformatics platforms. These platforms will be utilized and adopted to addre ...
Voir le projet
13
Participants partenaires
TERMINÉ
"Training in neurodegeneration, therapeutics intervention and neurorepair" (TINTIN)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
"Dopamine neurons play a central role in major illnesses, such as anxiety and mood disorders, schizophrenia, autism-spectrum disorders, Parkinson’s disease, epilepsy, and dementia. A multidisciplinary approach must be taken by European researchers to discover the molecular basis of dopamine neurodegeneration and how new technologies will lead to repair and regeneration of neuronal systems in the b ...
Voir le projet
8
Participants partenaires
TERMINÉ
Methods for high-throughput (HTP) analysis of protein glycosylation (HighGlycan)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2016,
Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associated with a wide range of diseases, including cancer, diabetes, as well as congenital, cardiovascular, immunological and infectious disorders. A number of studies identified potentially important glycan disease biomarkers. With regard to biotechnology, proper gl ...
Voir le projet
9
Participants partenaires
TERMINÉ
Tools for the Detection of Novel Glyco-biomarkers (GlycoBioM)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
Glycosylation patterns on glycoproteins and glycolipids are involved in the regulation of inter- and intracellular recognition events and alteration of such glycosylation has been observed in many diseases, notably in a variety of cancers. We propose that a systematic, large scale investigation in this area will provide a rich spectrum of novel and structurally diverse carbohydrate-based highly sp ...
Voir le projet
6
Participants partenaires
TERMINÉ
Glycomics by High-throughput Integrated Technologies (GlycoHIT)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2014,
Protein glycosylation is a post-translational phenomenon that is involved in most physiological and disease processes including cancer. Most of the known cancer-associated glycobiomarkers were discovered individually using liquid chromatography and mass spectroscopy. Though valuable, there is room for improvement in these approaches for the discovery phase. There is also a critical need for innova ...
Voir le projet
16
Participants partenaires
TERMINÉ
Development of carbohydrate array technology to systematically explore the functional role of glycans in healthy and diseased states (EuroGlycoArrays)
Date du début: 1 sept. 2008, Date de fin: 31 août 2012,
The development and production of glycoarrays will provide the foreground knowledge necessary to lead to a step change in the diagnosis and treatment of diseases ranging from cancers to autoimmune diseases. Carbohydrates play a pivotal role in the molecular interactions that govern biological events at the centre of health and disease. This has become more evident as the characterisation and ident ...
Voir le projet
17
Participants partenaires
TERMINÉ
Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders (SchizDX)
Date du début: 1 oct. 2008, Date de fin: 31 mars 2012,
Schizophrenia and bipolar affective disorder are a major burden to affected individuals and their families and to society at large. These two severe mental illnesses affect at least 2% of the population worldwide, and whilst 50% of sufferers do not receive adequate treatment, they cost hundreds of billions in healthcare provision, treatments and lost earnings. The current diagnosis of schizophreni ...
Voir le projet